Hansa Biopharma AB at UBS Global Healthcare Conference Transcript
Good morning, everyone, and welcome to the 2019 UBS Global Healthcare Conference. My name is Mallet Njonkem, and I'm happy to be your host this session. Now please join me in welcoming our next presenter, Mr. Emanuel Bjorn, Vice President of Global Business Development at Hansa Biopharma.
A breakout session will follow immediately after this presentation in the Julliard room. Thank you, and enjoy.
¶ - ()-
Thank you very much. My name is Emanuel Bjorn, and I'm Vice President, Global Business Development of Hansa Biopharma. We are based in Sweden. We have operations in the U.S. and in Europe. Let's see here.
Please take a look at our forward-looking statements slide here. And we are a clinical stage -- late clinical-stage biopharma development company. We're focused on acute autoimmune diseases and transplant rejection. And quite recently, media here in the U.S. and in Europe have noticed our clinical results. For
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |